Milestone Pharmaceuticals (NASDAQ:MIST) Trading 5% Higher

Share on StockTwits

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares traded up 5% during trading on Wednesday . The stock traded as high as $8.90 and last traded at $8.55. 278,976 shares changed hands during trading, a decline of 89% from the average session volume of 2,567,452 shares. The stock had previously closed at $8.14.

A number of analysts have issued reports on MIST shares. Jefferies Financial Group raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $3.00 to $15.00 in a report on Friday, July 24th. Zacks Investment Research downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Oppenheimer raised Milestone Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a report on Wednesday, July 29th. Cowen lifted their price target on Milestone Pharmaceuticals from $6.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, July 23rd. Finally, Piper Sandler lifted their price target on Milestone Pharmaceuticals from $3.00 to $8.00 and gave the stock a “neutral” rating in a report on Thursday, July 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $11.35.

The company has a fifty day moving average price of $8.32 and a two-hundred day moving average price of $6.38. The firm has a market capitalization of $211.27 million, a PE ratio of -3.46 and a beta of 4.79.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.02). As a group, research analysts forecast that Milestone Pharmaceuticals Inc. will post -2.19 EPS for the current year.

In other Milestone Pharmaceuticals news, major shareholder De Solidarite Des Travai Fonds sold 19,863 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $8.10, for a total transaction of $160,890.30. Following the completion of the sale, the insider now directly owns 2,754,920 shares of the company’s stock, valued at approximately $22,314,852. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.16% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG purchased a new stake in Milestone Pharmaceuticals during the 1st quarter valued at approximately $25,000. Two Sigma Advisers LP acquired a new position in Milestone Pharmaceuticals during the 2nd quarter worth approximately $79,000. California Public Employees Retirement System acquired a new position in Milestone Pharmaceuticals during the 2nd quarter worth approximately $120,000. Schonfeld Strategic Advisors LLC acquired a new position in Milestone Pharmaceuticals during the 2nd quarter worth approximately $125,000. Finally, Sphera Funds Management LTD. acquired a new position in Milestone Pharmaceuticals during the 1st quarter worth approximately $125,000. 39.42% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile (NASDAQ:MIST)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Read More: Market Indexes

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.